Human immunodeficiency virus type 1 envelope glycoprotein trimer (HIV-1 Env trimer)

The Human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein (Env) trimer is the sole viral protein on the surface of the HIV-1 virion and is essential for mediating entry into host cells (UniProt: P04578). It is synthesized as a gp160 precursor that is cleaved into gp120 and gp41 subunits, which then assemble into a metastable trimer of heterodimers. The gp120 subunit facilitates initial attachment to the host CD4 receptor and subsequent interaction with co-receptors like CCR5 or CXCR4, while gp41 drives the fusion of the viral and cellular membranes (PubMed: 24179158). Because it is the only target for neutralizing antibodies, the Env trimer is the primary focus of HIV-1 vaccine design, often utilizing stabilized mimics like SOSIP trimers to induce broadly neutralizing antibodies (bNAbs) (PubMed: 26643138). In therapeutic contexts, various bNAbs and entry inhibitors target specific conserved regions of the trimer, such as the CD4 binding site or the membrane-proximal external region (MPER), to prevent infection (NIH: NIAID). However, the high mutation rate of the virus and the presence of a dense "glycan shield" present significant challenges for both vaccine and drug development. Additionally, the conformational flexibility of the trimer allows it to transition between "closed" and "open" states, further complicating the elicitation of effective immune responses. Current research focuses on engineering next-generation immunogens that can overcome these barriers to provide long-lasting protection against diverse HIV-1 strains.

Other names

gp160 trimergp140 trimerSOSIP trimerHIV-1 Env spikeEnvelope glycoprotein complexgp120/gp41 complex

The trimer mediates viral entry by binding to host CD4 and co-receptors (CCR5/CXCR4), followed by a conformational change that triggers gp41-mediated membrane fusion; as an immunogen, it is designed to elicit broadly neutralizing antibodies (bNAbs) that block these processes.